XML 39 R27.htm IDEA: XBRL DOCUMENT v3.25.2
Collaborations, contracts and licensing agreements (Tables)
6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of deferred collaborations and contracts revenue The following table outlines the transaction price and the changes to the related liability balance:
Transaction PriceCumulative Collaboration Revenue RecognizedDeferred License Revenue
(in thousands)
Combined performance obligation$50,445 $50,445 $— 
Less contract asset— 
Total deferred license revenue$— 
Summary of collaborations
Revenues are summarized in the following table:
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
(in thousands)(in thousands)
Revenue from collaborations and licenses
Acuitas Therapeutics, Inc.$591 $642 $1,095 $1,337 
Qilu Pharmaceutical Co., Ltd.9,622 513 10,434 757 
Non-cash royalty revenue
Alnylam Pharmaceuticals, Inc.526 571 974 1,164 
Total revenue$10,739 $1,726 $12,503 $3,258